ArriVent BioPharma, Inc.
AVBP
Analytical Summary
ArriVent BioPharma, Inc. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.
4-Year Financial Trajectory
AnnualBullish Indicators
- No bullish signals detected.
Bearish Risks
- Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile
Health Breakdown
Statement lens
Choose the reporting cadence, isolate a period range, or search directly for a metric.
| Metric | FY 2025 Dec 31, 2025 10-K ↗ | FY 2024 Dec 31, 2024 10-K ↗ | FY 2023 Dec 31, 2023 10-K ↗ | FY 2022 Dec 31, 2022 10-K ↗ |
|---|---|---|---|---|
| EPS Growth YoY (%) |
-68.8%
Weak
Weak
Year-over-year change in earnings per share
Optimal:
> 10%
|
92.1%
Excellent
Excellent
Year-over-year change in earnings per share
Optimal:
> 10%
|
— | — |
| Net Income Growth YoY (%) |
-106.6%
Weak
Weak
Year-over-year change in net income |
-16.1%
Weak
Weak
Year-over-year change in net income |
— | — |
| FCF Growth YoY (%) |
-87.1%
Weak
Weak
Year-over-year change in free cash flow |
91.4%
Excellent
Excellent
Year-over-year change in free cash flow |
— | — |
| Metric | FY 2025 Dec 31, 2025 10-K ↗ | FY 2024 Dec 31, 2024 10-K ↗ | FY 2023 Dec 31, 2023 10-K ↗ | FY 2022 Dec 31, 2022 10-K ↗ |
|---|---|---|---|---|
| FCF / Net Income (x) |
0.97x
Caution
↑
Caution
Improving
Free cash flow relative to reported net income
Optimal:
> 1x
|
0.87x
Caution
Caution
Free cash flow relative to reported net income
Optimal:
> 1x
|
0.81x
Caution
Caution
Free cash flow relative to reported net income
Optimal:
> 1x
|
— |
| Metric | FY 2025 Dec 31, 2025 10-K ↗ | FY 2024 Dec 31, 2024 10-K ↗ | FY 2023 Dec 31, 2023 10-K ↗ | FY 2022 Dec 31, 2022 10-K ↗ |
|---|---|---|---|---|
| Return on Invested Capital (%) |
-45.7%
Weak
↓
Weak
Declining
Return earned on debt + equity capital invested
Optimal:
> 10%
|
-28.9%
Weak
Weak
Return earned on debt + equity capital invested
Optimal:
> 10%
|
38.5%
Excellent
Excellent
Return earned on debt + equity capital invested
Optimal:
> 10%
|
— |
| Return on Capital (%) (%) |
-53.3%
Weak
↓
Weak
Declining
Operating profit relative to total assets
Optimal:
> 10%
|
-34.3%
Weak
Weak
Operating profit relative to total assets
Optimal:
> 10%
|
-45.7%
Weak
Weak
Operating profit relative to total assets
Optimal:
> 10%
|
— |
| Return on Common Equity (%) (%) |
-54.1%
Weak
↓
Weak
Declining
Profit generated per dollar of shareholder equity
Optimal:
> 15%
vs Sector:
Below avg (-461%)
|
-31.2%
Weak
Weak
Profit generated per dollar of shareholder equity
Optimal:
> 15%
vs Sector:
Below avg (-308%)
|
45.3%
Excellent
Excellent
Profit generated per dollar of shareholder equity
Optimal:
> 15%
vs Sector:
Above avg (+202%)
|
— |
Secondary lens
Benchmark Lens
Compare AVBP against peers after checking the statement evidence.
Open lens
Benchmark Lens
Compare AVBP against peers after checking the statement evidence.
Signals
Key bullish and bearish indicators for AVBP
No bullish signals detected
Return on Common Equity (%) is in the bottom quartile
Percentile Rankings
How AVBP compares to all companies
Peer Comparison
AVBP vs similar peers
Compare AVBP with peers
Stack AVBP against similar companies across every metric on this page.
north_east Open comparisonbar_chart Data from SEC EDGAR XBRL filings
Synced 1 week ago 4 years · 14 quarters